A detailed history of Two Sigma Investments, LP transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Two Sigma Investments, LP holds 1,145,331 shares of NUVB stock, worth $3.32 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,145,331
Previous 1,069,801 7.06%
Holding current value
$3.32 Million
Previous $3.12 Million 15.66%
% of portfolio
0.01%
Previous 0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.3 - $3.83 $173,719 - $289,279
75,530 Added 7.06%
1,145,331 $2.63 Million
Q2 2024

Aug 14, 2024

SELL
$2.58 - $3.69 $217,380 - $310,904
-84,256 Reduced 7.3%
1,069,801 $3.12 Million
Q1 2024

May 15, 2024

SELL
$1.46 - $3.97 $523,135 - $1.42 Million
-358,312 Reduced 23.69%
1,154,057 $4.2 Million
Q4 2023

Feb 14, 2024

BUY
$0.96 - $1.53 $854,505 - $1.36 Million
890,110 Added 143.04%
1,512,369 $2.28 Million
Q3 2023

Nov 14, 2023

BUY
$1.26 - $2.1 $67,505 - $112,509
53,576 Added 9.42%
622,259 $833,000
Q2 2023

Aug 14, 2023

BUY
$1.56 - $1.84 $181,939 - $214,595
116,628 Added 25.8%
568,683 $1.02 Million
Q1 2023

May 15, 2023

SELL
$1.6 - $2.48 $383,712 - $594,753
-239,820 Reduced 34.66%
452,055 $750,000
Q4 2022

Feb 14, 2023

BUY
$1.68 - $2.5 $270,298 - $402,230
160,892 Added 30.3%
691,875 $1.33 Million
Q3 2022

Nov 14, 2022

BUY
$0.29 - $4.04 $52,254 - $727,963
180,189 Added 51.37%
530,983 $1.19 Million
Q2 2022

Aug 15, 2022

BUY
$3.24 - $5.85 $811,474 - $1.47 Million
250,455 Added 249.61%
350,794 $1.14 Million
Q1 2022

May 16, 2022

BUY
$4.6 - $8.83 $461,559 - $885,993
100,339 New
100,339 $528,000

Others Institutions Holding NUVB

About Nuvation Bio Inc.


  • Ticker NUVB
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 217,244,000
  • Market Cap $630M
  • Description
  • Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...
More about NUVB
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.